Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bella Ungar

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
The Lancet. Gastroenterology & Hepatology|April 22, 2021
Infliximab discontinuation in patients with ulcerative colitisBella Ungar
United European Gastroenterology Journal|August 4, 2020
Long-term outcome of ulcerative proctitisBella Ungar, Uri Kopylov
Annals of Gastroenterology|July 2, 2016
Advances in the development of new biologics in inflammatory bowel diseaseBella Ungar, Uri Kopylov
United European Gastroenterology Journal|October 3, 2022
Does pan-enteric capsule endoscopy obviate magnetic resonance entero-colonography in suspected Crohn's disease?Bella Ungar, Rami Eliakim
Alimentary Pharmacology & Therapeutics|April 15, 2020
Editorial: is vedolizumab effective for perianal Crohn's disease?Bella Ungar, Uri Kopylov
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 11, 2016
ReplyShomron Ben-Horin, Bella Ungar
Alimentary Pharmacology & Therapeutics|January 29, 2022
Letter: loss of response to anti-TNFα agents in patients with inflammatory bowel disease depends on treatment durationShomron Ben-Horin, Bella Ungar
Alimentary Pharmacology & Therapeutics|February 28, 2019
Letter: double-dose intensification-a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors replyBella Ungar, Shomron Ben Horin, Xavier Roblin
Journal of Crohn'S & Colitis|January 31, 2016
Infliximab Efficacy and Safety in an Ulcerative Colitis Patient with Systemic Lupus ErythematosusShomron Ben-Horin, Bella Ungar, Rami Eliakim, et al.
United European Gastroenterology Journal|March 27, 2024
A Gastroenterologist's guide to drug interactions of small molecules for inflammatory bowel diseaseSivan Harnik, Bella Ungar, Ronen Loebstein, et al.
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
The Lancet. Gastroenterology & Hepatology|April 22, 2021
Infliximab discontinuation in patients with ulcerative colitisBella Ungar
United European Gastroenterology Journal|August 4, 2020
Long-term outcome of ulcerative proctitisBella Ungar, Uri Kopylov
Annals of Gastroenterology|July 2, 2016
Advances in the development of new biologics in inflammatory bowel diseaseBella Ungar, Uri Kopylov
United European Gastroenterology Journal|October 3, 2022
Does pan-enteric capsule endoscopy obviate magnetic resonance entero-colonography in suspected Crohn's disease?Bella Ungar, Rami Eliakim
Alimentary Pharmacology & Therapeutics|April 15, 2020
Editorial: is vedolizumab effective for perianal Crohn's disease?Bella Ungar, Uri Kopylov
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 11, 2016
ReplyShomron Ben-Horin, Bella Ungar
Alimentary Pharmacology & Therapeutics|January 29, 2022
Letter: loss of response to anti-TNFα agents in patients with inflammatory bowel disease depends on treatment durationShomron Ben-Horin, Bella Ungar
Alimentary Pharmacology & Therapeutics|February 28, 2019
Letter: double-dose intensification-a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors replyBella Ungar, Shomron Ben Horin, Xavier Roblin
Journal of Crohn'S & Colitis|January 31, 2016
Infliximab Efficacy and Safety in an Ulcerative Colitis Patient with Systemic Lupus ErythematosusShomron Ben-Horin, Bella Ungar, Rami Eliakim, et al.
United European Gastroenterology Journal|March 27, 2024
A Gastroenterologist's guide to drug interactions of small molecules for inflammatory bowel diseaseSivan Harnik, Bella Ungar, Ronen Loebstein, et al.
Pageof 9